Skip to main content
. 2011 Dec 16;26(3):426–433. doi: 10.1038/eye.2011.324

Table 3. Improvement of visual acuity with follow-up.

logMAR Gain of ≥ 0.3 Baseline 3 Months 6 Months 9 Months 12 Months
Bevacizumab (%) Reference 9 (13.6%) 11 (16.7%) 13 (19.7%) 12 (18.2%)
Ranibizumab (%) Reference 10 (16.7%) 14 (23.3%) 13 (21.7%) 14 (23.3%)
Pa   0.53 0.12 0.32 0.29

Abbreviation: logMAR, logarithm of the minimum angle of resolution.

a

On the basis of χ2 test.